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Oral Presentations 31Background:Little is known about the prevention practices used
by HCT centers internationally to prevent herpesvirus and fungal
infections. The purpose of this survey was to compare prevention
strategies by geographic region, center size and patient population
(pediatric vs. adult).Methods: A web-based questionnaire was dis-
tributed to Program Directors at CIBMTR-affiliated HCT centers
to elicit information on the strategies used to prevent HSV, VZV,
CMV and fungal diseases at each institution between 1999 and
2003. Results: The response rate was 80% (n 5 174) from HCT
centers in 32 countries, including the US/Canada (n5 96), Europe
(n5 40), Australia and New Zealand (n5 13), Latin America (n 5
12), Asia (n5 6), the Middle East (n5 4) and South Africa (n5 3).
While short-course acyclovir (ACV) for HSV prophylaxis was used
almost uniformly, 62% of centers routinely used prophylactic low-
dose ACV or similar agents as prophylaxis against VZV; of these,
19% treated for 1 month or less, 29% for 3–4 mos., 9% for 6–9
mos., 26% for 12 mos. and 17% until off immunosuppressants or
until immune reconstitution. Strategies to prevent CMV disease
in seropositive recipients were used in the following proportions:
high-dose ACV/VACV alone (3%), Ganciclovir-based (GCV) pro-
phylaxis alone (5%), surveillance and preemptive therapy (PET)
alone (47%) or a combination strategy (45%) most commonly
high-dose ACV and PET.The prevention strategies used in Europe
were very similar to those used in theUSwith the exception of high-
dose ACV/VACV which was used routinely by 48% of European
centers compared with 25% of US centers (P\ .05, Fisher exact
test). In Australia and NZ (grouped together), GCV prophylaxis
was used in higher proportions than in the US, Europe and Canada
(54% vs. 23%, P\ .05). Routine antifungal prophylaxis was used by
78% and 57% of European and Canadian centers, respectively,
compared with its use in the US (97%), Australia/NZ (100%),
and Latin America (100%). Also, antifungal prophylaxis was more
commonly used in pediatric centers than in adult-only centers
(97% vs 85%). Practices among smaller centers were remarkably
similar to those in high-volume centers (.50 HCTs annually).
Other trends in prevention strategies will be presented at the con-
ference. Conclusion: This large analysis sheds light on current
practices being employed globally to prevent herpesvirus and fungal
diseases in HCT recipients and highlights previously unknown dif-
ferences in prevention strategies.77
IMPACT OF RIBAVIRIN THERAPY ON RESPIRATORY SYNCITIAL VIRUS
INFECTION FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
Kodali, D., Cao, Q., Young, J., Orchard, P., Burns, L.J. University of
Minnesota, Minneapolis, MN.
Respiratory syncitial virus (RSV) infections are associated with
high morbidity and mortality among hematopoietic cell transplan-
tation (HCT) recipients. We conducted a retrospective cohort
study to determine the impact of ribavirin therapy on RSV infec-
tion, defined as respiratory symptoms with a nasopharyngeal (NP)
or bronchial lavage positive RSV assay/culture. Of 3648 HCT re-
cipients between January 1986 and August 2005, 109 (median age
32 years, range 0.6–64) were diagnosed with RSV infection; the
overall incidence was 3% (95% confidence intervals [CI], 2.5–
3.6%). Sixty-nine patients received aerosolized ribavirin therapy
(RT) and 40 did not (noRT). Median follow-up was 1.1 (range 0–
18.6) years and 4.7 (range, 0–20.0) years for the RT and noRT
groups (p 5 .01), respectively. The two groups were comparable
with respect to age, conditioning regimen, gender, donor type, un-
derlying disease, cytomegalovirus serology, transplant year, GVHD
prophylaxis and incidence, time to neutrophil recovery, NP swab
positive assay/culture and evidence of co-infections at time of diag-
nosis of RSV infection. RT patients had a shorter time from trans-
plant to RSV diagnosis (63 vs. 159 days, p\0.01), were less likely to
have neutrophil engraftment (66% vs. 85%, p 5 0.02), and were
more likely to have lower respiratory infection (LRI) as evidenced
by pulmonary infiltrates on CXR (80% vs. 27%, p\0.01). RSV in-
fection resolved in 44 patients (63%) of the RT group compared
with 37 (90%) patients in the noRT group (p 5 0.01); RSV related
deaths occurred in 15 (21%) RT patients and 1 (2%) noRT patient.
In the RT group, patients who failed therapy were more likely tohave LRI (96% vs. 68%, p\ 0.01), lack of neutrophil engraftment
(46% vs. 77%, p 5 0.01), shorter time from transplant to RSV di-
agnosis (17 days vs. 79 days, p5 0.01) and presence of co-infections
(54% vs. 16%, p\0.01).Multivariate analysis revealed the presence
of co-infections as the only predictive factor in lack of resolution of
RSV infection in the RT group (relative risk 2.54, 95% CI 1.49–
4.3). We conclude that RSV infected patients with neutrophil en-
graftment and no evidence of LRI often improve without ribavirin
therapy and can be closely monitored. In contrast, mortality re-
mains high despite ribavirin therapy in patients with LRI, lack of en-
graftment, and co-infections.78
CHRONIC HEPATITIS C, CIRRHOSIS, AND END STAGE LIVER DISEASE
AMONG 30-YEAR SURVIVORS OF BONE MARROW TRANSPLANT
Pergam, S.A.1, Strasser, S.I.2, Flowers, M.E.1, Sullivan, K.M.3,
McDonald, G.B.1. 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Sydney - AW Morrow Gastroenterology and Liver
Centre, Camperdown, Australia; 3Duke University Medical Center,
Durham, NC.
Introduction: For long-term survivors who received a bonemar-
row transplant (BMT) before the discovery of hepatitis C virus
(HCV), chronic HCV infection is a common complication. We
evaluated a cohort of BMT recipients from the pre-HCV screening
era to determine the frequency of progression to cirrhosis and End
Stage Liver Disease (ESLD) along with relevant risk factors.
Methods: We reviewed the course of a total of 134 patients trans-
planted at the Fred Hutchinson Cancer Center (FHCRC) in Seat-
tle, WA before June 1978 who survived over 10 years after BMT.
We retrospectively collected data using the FHCRC Long-Term
Follow-Up database, which includes data from periodic on-site ex-
aminations, all available outside records, laboratory tests, and yearly
questionnaires. A priori risk factors thought to be associated with
cirrhosis and ESLD were assessed using chi-squared and Wil-
coxon-rank sum analyses. Results: A total of 134 patients met cri-
teria for inclusion in the study, of which 9 were lost to follow-up,
leaving 125 evaluable patients. 82 (66%) were still alive at a median
28.6 years (24.0–35.5); 43 (34%) had died at a median 20.4 years
(10.1–31.9). HCV status was known in 94 survivors: 58 (62%)
were HCV-infected patients, of whom 7 cleared the virus. Among
51 chronically HCV-infected patients, 34 (67%) developed chronic
liver disease. Cirrhosis developed in 14/51 (27%) of these chroni-
cally infected patients, 10 of whom progressed to ESLD. Four total
ESLD patients underwent orthotopic liver transplant, 3 for decom-
pensated cirrhosis and 1 for cirrhosis with hepatocellular carcinoma
(HCC). One other patient with ESLD developed HCC. Cirrhosis
(p\0.01) and ESLD (p 5 0.02) were associated with HCV status,
but not with gender, age at transplant, diagnosis, conditioning ther-
apy, post-BMT immunosuppression, hepatitis B status, history of
graft-versus-host-disease, or history of sinusoidal obstruction syn-
drome. Conclusions: In this unique cohort of long-term survivors
of BMT with over 30 years of follow-up, a large portion of patients
were infected with HCV and most developed chronic HCV infec-
tion. Those with chronic infection are at high risk of developing cir-
rhosis and ESLD. Our data indicate that HCV infection is
a significant cause of morbidity and mortality in these patients.79
PEGFILGRASTIM (P) APPEARS TO BE EQUIVALENT TO MULTIPLE DAILY
DOSES OF FILGRASTIM (F) TO TREAT NEUTROPENIA POST-AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN PA-
TIENTS WITH NON-HODGKIN’S LYMPHOMA: RESULTS OF
A RANDOMIZED PHASE II TRIAL
Rifkin, R., Beveridge, R., Spitzer, G., Orloff, G., Mandanas, R.,
McGaughey, D., Zhan, F., Boehm, K., Asmar, L. Blood and Marrow
Transplant Network, US Oncology, Houston, TX.
Filgrastim has previously been shown to decrease the time to neu-
trophil recovery following autologous PBSCT. Therefore, it was
hypothesized that a single injection of pegfilgrastim (P) would
